Insulet Co. (NASDAQ:PODD) SVP Dan Manea Sells 200 Shares of Stock

Insulet Co. (NASDAQ:PODDGet Rating) SVP Dan Manea sold 200 shares of the stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $294.62, for a total value of $58,924.00. Following the completion of the sale, the senior vice president now owns 3,158 shares of the company’s stock, valued at approximately $930,409.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Insulet Trading Down 1.7 %

Shares of NASDAQ PODD opened at $290.60 on Tuesday. The company has a market cap of $20.18 billion, a price-to-earnings ratio of 1,210.83 and a beta of 0.79. Insulet Co. has a 12-month low of $181.00 and a 12-month high of $320.00. The company has a current ratio of 3.98, a quick ratio of 3.00 and a debt-to-equity ratio of 3.22. The stock’s 50 day simple moving average is $254.70 and its 200 day simple moving average is $240.92.

Institutional Trading of Insulet

Several hedge funds have recently made changes to their positions in PODD. William Blair Investment Management LLC bought a new stake in shares of Insulet in the 1st quarter worth approximately $136,901,000. Clearbridge Investments LLC lifted its holdings in shares of Insulet by 38.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after purchasing an additional 474,545 shares during the last quarter. Echo Street Capital Management LLC lifted its holdings in shares of Insulet by 60.8% in the 1st quarter. Echo Street Capital Management LLC now owns 802,434 shares of the medical instruments supplier’s stock worth $213,760,000 after purchasing an additional 303,355 shares during the last quarter. Lord Abbett & CO. LLC increased its position in Insulet by 652.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 298,819 shares of the medical instruments supplier’s stock valued at $68,549,000 after acquiring an additional 259,089 shares during the period. Finally, Renaissance Technologies LLC increased its position in Insulet by 106.9% in the 1st quarter. Renaissance Technologies LLC now owns 182,900 shares of the medical instruments supplier’s stock valued at $48,723,000 after acquiring an additional 94,500 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PODD. Robert W. Baird raised their price objective on Insulet from $300.00 to $315.00 and gave the company an “outperform” rating in a research note on Friday, November 4th. Barclays began coverage on Insulet in a research note on Monday, October 17th. They set an “equal weight” rating and a $238.00 price objective for the company. BTIG Research raised their price objective on Insulet from $285.00 to $320.00 in a research note on Friday, November 4th. Piper Sandler upgraded Insulet from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $235.00 to $340.00 in a research note on Friday, November 4th. Finally, Canaccord Genuity Group raised their price objective on Insulet from $250.00 to $290.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $300.62.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Featured Stories

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.